Appointment dossier — Mucinous Ovarian Tumors
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Mucinous Ovarian Tumors
Compounds named in the cited literature for Mucinous Ovarian Tumors, labeled by the strongest evidence found:
- anti-HER2 therapy — Named in the literature
- appendectomy — Named in the literature
- appendicectomy — Named in the literature
- capecitabine and oxaliplatin — Named in the literature
- carboplatin and paclitaxel — Named in the literature
- mirvetuximab soravtansine (MIRV) — Named in the literature
- PARP inhibitors — Named in the literature
- PD-1/PD-L1 inhibitors — Named in the literature
- primary cytoreductive surgery — Named in the literature
Open recruiting trials (18)
- NCT07488676 · Phase 1 / Phase 2 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (United States)
- NCT05512208 · Phase 2 — A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (United States)
- NCT07612891 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor (China)
- NCT05086692 · Phase 1 / Phase 2 — A Beta-only IL-2 ImmunoTherapY Study (United States)
- NCT06545942 · Phase 1 — Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (United States)
- NCT06215950 · Phase 1 — A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer (China)
- NCT07782164 — Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) (Netherlands)
- NCT06824467 · Phase 3 — A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (United States)
- NCT02429687 · Phase 3 — TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (China)
- NCT05112601 · Phase 2 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (United States)
- NCT05123807 · Phase 2 — Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) (United States)
- NCT04520139 · Phase 1 / Phase 2 — Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT (United States)
- NCT07285044 · Phase 2 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (United States)
- NCT04918186 · Phase 2 — Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (United States)
- NCT07311577 · Phase 2 — Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study (China)
- NCT03604315 · Phase 1 — Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF (United States)
- NCT05969041 · Phase 1 — Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (Australia)
- NCT02073500 — Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies (Norway)
Most-relevant first: trials that name Mucinous Ovarian Tumors, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT07488676), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?